DOT Transportation Workplace Drug and Alcohol Testing

The Department of Transportation's 49 CFR Part 40 — Procedures for Transportation Workplace Drug and Alcohol Testing Programs — establishes a uniform testing framework that applies to every DOT-regulated transportation mode: commercial truck and bus drivers (FMCSA), airline pilots and flight crew (FAA), railroad workers (FRA), mass transit operators (FTA), pipeline operators (PHMSA), and maritime personnel (USCG). The rule covers approximately 12 million safety-sensitive transportation employees — workers whose impairment while performing their function could directly endanger themselves, their passengers, or the public. Part 40 is the procedural backbone; each modal agency (FAA Part 120, FMCSA Part 382, FRA Part 219, FTA Part 655) specifies which positions are safety-sensitive and mandates employer program requirements. Every DOT drug test uses a 5-panel urine test for marijuana, cocaine, amphetamines, opioids, and PCP analyzed at an HHS-certified laboratory. Alcohol testing uses evidential breath testing (EBT) devices. Testing is required in six circumstances: pre-employment (before first performance of safety-sensitive duties), random (unannounced, throughout the year), post-accident (following accidents meeting threshold criteria), reasonable suspicion (based on specific observations by a trained supervisor), return-to-duty (before resuming safety-sensitive work after a violation), and follow-up (1–5 years of unannounced testing after return to duty).

Current Rule (2026)

Legal Authority

• 49 U.S.C. § 31306 — Commercial motor vehicle operators (CDL holders): DOT must issue regulations requiring drug testing of operators subject to FMCSA commercial vehicle regulations
• 49 U.S.C. § 45102 — Aviation employees: FAA must prescribe drug and alcohol testing for employees performing safety-sensitive aviation functions
• 49 U.S.C. § 20140 — Railroad employees: FRA authority for drug and alcohol testing in rail operations
• 49 U.S.C. § 5331 — Transit employees: FTA authority for drug and alcohol testing in federally assisted mass transit systems

Implementing Regulations (49 CFR Part 40)

• Subpart B — Employer Responsibilities (10s): employers must ensure all safety-sensitive employees are in a compliant drug and alcohol testing program; employers may use Third-Party Administrators (TPAs) but retain full legal responsibility for program compliance (§ 40.15); before hiring/transferring into safety-sensitive positions, employers must check prospective employee's drug/alcohol history for the prior 2 years (§ 40.25); employers report annual Management Information System (MIS) data to their modal agency on testing rates and results
• Subpart D — Collection Sites, Forms, and Equipment (10s): urine collection must take place at a qualified collection site with specific privacy requirements; the Federal Drug Testing Custody and Control Form (CCF) documents chain of custody from collection through lab analysis; collection sites must have approved specimen containers; direct observation collection required when a previous specimen was rejected, when results were substituted/adulterated, or when the collector observes conduct suggesting tampering
• Subpart E — Specimen Collections (10s): collector must verify donor identity (photo ID), ensure the collection container is new and undamaged, observe handwashing, measure specimen temperature within 4 minutes (90–100°F for valid in-range), check for signs of adulteration/dilution; the specimen is split into Bottle A (primary, sent to lab) and Bottle B (split specimen, stored for potential retesting); specimens below minimum volume (30 mL) trigger a shy bladder procedure — employee given up to 3 hours with water to produce an adequate specimen; inability to produce under medical supervision is treated as a refusal
• Subpart F — Drug Testing Laboratories (18s): only HHS-certified laboratories may analyze DOT drug test specimens; laboratories must maintain certification and pass proficiency tests; DOT agencies and employers may inspect laboratories at any time (§ 40.107); labs must retain positive and non-negative specimens for one year and negative specimens for 60 days; statistical summaries must be provided to employers on request (§ 40.111); labs may not have financial arrangements with MROs that could compromise objectivity (§ 40.101)
• Subpart G — Medical Review Officers and Verification (23s): the MRO is the gatekeeper of the drug testing program — a licensed physician with specific MRO training who reviews every non-negative result before it is reported to the employer; MRO contacts the employee directly to determine whether a legitimate medical explanation exists for the result (§ 40.129); MRO may verify a result positive without employee interview in limited circumstances (§ 40.133); MROs must verify results based on specific clinical criteria for each drug class — marijuana, cocaine, amphetamines, opioids, PCP (§§ 40.137–40.145); after verification, MRO reports result to the Designated Employer Representative (DER) — verified positive, refusal, canceled, or negative; MROs may not work for laboratories whose specimens they review
• Subpart H — Split Specimen Tests (9s): after receiving an MRO-verified positive, adulterated, or substituted result, the employee has 72 hours to request a split specimen analysis at a different HHS-certified laboratory; the employer must pay for the split test if requested; if the split specimen confirms the primary result, the MRO's verification stands; if the split does not confirm (insufficient specimen, wrong drugs detected), the MRO cancels the test — the result becomes negative and the employer cannot take action; this right is fundamental — the MRO must advise the employee of the right to a split test
• Subpart I — Problems in Drug Tests (12s): test errors fall into two categories: fatal flaws that must result in test cancellation (specimen ID doesn't match, no collector's signature on CCF, primary specimen seal broken with no documentation) vs. correctable flaws that can be cured by sworn affidavit (collector signed on the wrong line, incorrect lab copy of CCF) within 60 days; canceled tests are not positive results and cannot be used as the basis for adverse action — the employer must direct the employee to a retest (usually not observed for the first retest)
• Subpart N — Problems in Alcohol Testing (9s): EBT device must show passing calibration check; if the initial screen is 0.02% or above, a confirmation test on a DOT-approved evidential breath testing device is required within 15–30 minutes; problems include invalid results (device malfunction), refusals, and insufficient breath volume; similar fatal/correctable flaw framework as drug testing
• Subpart O — Substance Abuse Professionals and Return-to-Duty (16s): after a violation (positive, refusal, or actual knowledge), the employee must be immediately removed from safety-sensitive functions and evaluated by a Substance Abuse Professional (SAP) — a licensed clinician trained in addiction assessment; the SAP recommends education or treatment; the employee must complete the SAP's recommendation and undergo a return-to-duty test (must be negative for drugs, or below 0.02% for alcohol) before resuming safety-sensitive work; after returning to duty, the employee is subject to follow-up testing for 1–5 years (minimum 6 unannounced tests in the first year), scheduled and unannounced, in addition to the regular random testing pool
• Subpart Q — Service Agent Roles and Responsibilities (8s): service agents (TPAs, collectors, MROs, SAPs, labs) must follow Part 40 procedures as if they were the employer; service agents must provide records to employers on request; service agents cannot advertise services in ways that misrepresent DOT program requirements; service agents are subject to public interest exclusions
• Subpart R — Public Interest Exclusions (27s): DOT may prohibit service agents who engage in serious or repeated violations from providing services to DOT-regulated employers; the PIE process includes notice, opportunity to respond, and a formal decision; PIE-excluded service agents are listed on DOT's public website; employers must check the list before contracting with new service agents; typically used against labs, TPAs, or SAPs who falsified results, failed proficiency tests, or otherwise compromised program integrity

FMCSA-Specific Requirements (49 CFR Part 382)

The FMCSA's modal-specific rule — 49 CFR Part 382 — applies Part 40's procedural framework to commercial motor vehicle (CMV) operations and adds requirements specific to the 6.4 million CDL holders and their employers. Key provisions:

• § 382.201 — Alcohol concentration limit: 0.04 BAC is the operational threshold for CDL drivers — the same 0.04 standard applies in aviation; drivers with BAC 0.02–0.039 are removed from safety-sensitive duty for 24 hours (§ 382.505) but not reported as a violation
• § 382.207 — Pre-duty alcohol restriction: no CDL driver may perform safety-sensitive functions within 4 hours after using alcohol; employers with actual knowledge of a violation must remove the driver
• § 382.303 — Post-accident testing: alcohol testing within 2 hours (up to 8 hours) and drug testing within 32 hours after qualifying accidents; qualifying accidents include fatal crashes and any crash where the driver receives a citation and either a vehicle is towed or someone requires medical treatment away from the scene
• § 382.305 — Random testing rates: minimum 50% of average driver count for controlled substances and 10% for alcohol per year (rates can be adjusted by FMCSA based on industry-wide positive test rates); random selection must be spread reasonably throughout the year — not concentrated in any single period
• § 382.301 — Pre-employment drug testing: required before first safety-sensitive duty; no pre-employment alcohol testing required, but employers may conduct it; employers must check the Clearinghouse before the first safety-sensitive duty regardless of prior testing

CDL Drug and Alcohol Clearinghouse (Subpart G — §§ 382.701–382.727): The Clearinghouse, launched January 6, 2020, is the most significant structural addition to the CDL drug and alcohol program in decades — a federal database operated by FMCSA that records every CDL driver's drug and alcohol program violations, refusals, and return-to-duty status:

• § 382.701 — Pre-employment query required: employers must query the Clearinghouse before a driver's first safety-sensitive duty and must obtain a negative result (or confirm no record exists) before the driver performs CDL-regulated work; no discretion to bypass — this is mandatory
• § 382.703 — Consent: employers must obtain driver's written or electronic consent before querying; drivers may see their own records at any time without fee (§ 382.721)
• § 382.705 — Reporting obligations: Medical Review Officers must report positive, adulterated, or substituted results within 2 business days; employers report actual knowledge violations and refusals; SAPs report return-to-duty eligibility; the reporting chain is multi-party and mandatory
• § 382.711 — Registration: all employers, TPAs, and other service agents must register with the Clearinghouse before accessing or reporting; registration is valid for 5 years and can be revoked for misuse (§ 382.713)
• § 382.719 — Removal of records: a violation record becomes unavailable to future employers only after the driver has completed the full return-to-duty process, the SAP has determined the driver is fit, and the driver has either completed the follow-up testing plan or 5 years have passed — whichever comes later; violations are never deleted but become inaccessible to employers after the retention window

The Clearinghouse eliminated the prior system's critical gap: employers could hire drivers with drug/alcohol violations at prior carriers without knowing, because paper record transfers were voluntary and easily circumvented. As of 2025, the Clearinghouse contains records on roughly 175,000 CDL drivers with active violations — a substantial fraction of the workforce who under the old system might have quietly obtained CDL jobs at new carriers.

Recent rulemaking: 89 FR 90619 (November 2024) updated Clearinghouse query requirements for state licensing authorities — as of November 18, 2024, states must query the Clearinghouse before issuing, renewing, upgrading, or transferring a CDL to ensure drivers with unresolved violations cannot obtain a new license simply by moving to a different state.

FTA-Specific Requirements (49 CFR Part 655)

The FTA's modal rule — 49 CFR Part 655 — applies Part 40's procedural framework to FTA-funded transit systems: bus operators, light rail and heavy rail operators, commuter rail, demand-responsive services, and contract operators providing service for FTA grant recipients. Part 655 covers safety-sensitive transit employees: vehicle operators, controllers (dispatchers), mechanics, armed security, and persons who carry out maintenance or repair of revenue service vehicles or equipment. Key provisions:

• § 655.3 — Applicability: Part 655 applies to every FTA grant recipient, subrecipient, and their contractors that receive federal assistance under 49 U.S.C. Chapter 53; the rule covers both direct recipients (large transit authorities) and subrecipients (smaller transit agencies receiving pass-through funding); contractors who operate transit service under contract to a recipient are covered directly — not through the recipient's program
• § 655.11–655.12 — Required program elements: each covered employer must have a written anti-drug and alcohol misuse policy adopted by the employer's local governing board; the policy must include a statement of covered employees' obligations, a description of prohibited conduct, a description of the testing circumstances, and a description of the consequences of violations; employers must also provide education materials to all covered employees and training to supervisors authorized to make reasonable suspicion determinations
• § 655.21 — Drug testing circumstances: pre-employment (before first safety-sensitive duty), post-accident, random, reasonable suspicion, return-to-duty, and follow-up; the transit-specific threshold for post-accident testing (§ 655.44): testing required following any accident involving a fatality; for non-fatal accidents, testing required when an operator receives a citation AND either the vehicle must be towed from the scene OR any person requires medical treatment away from the scene — the same threshold as FMCSA Part 382
• § 655.31 — Alcohol testing: all six testing circumstances apply; unlike drug testing, pre-employment alcohol testing is optional (not mandatory) for FTA-covered employers — a significant distinction from some other DOT modal rules
• § 655.32 — On-duty alcohol prohibition: an employer must prohibit a covered employee from using alcohol while performing safety-sensitive functions; an employer with actual knowledge that a covered employee has used alcohol while performing safety-sensitive functions must remove the employee from duty immediately
• § 655.33 — Pre-duty alcohol restriction: no covered employee may use alcohol within 4 hours before performing safety-sensitive functions; this is a bright-line prohibition independent of measured impairment; an employee who reports for duty showing signs of alcohol use within the 4-hour window must not be assigned safety-sensitive duties regardless of BAC
• § 655.34 — Post-accident alcohol restriction: an employee who is required to take a post-accident alcohol test under § 655.44 must not consume alcohol for 8 hours following the accident — or until tested, whichever comes first; this preserves the integrity of the post-accident test by preventing the employee from consuming alcohol to explain a later-measured BAC
• § 655.35 — BAC thresholds: a covered employee found to have a BAC of 0.04 or higher must be removed from safety-sensitive duty and referred to a SAP; an employee with a BAC of 0.02–0.039 must be removed from safety-sensitive duty for 24 hours — but this lower-level finding is not a reportable violation for FTA management information purposes (unlike FMCSA, which treats 0.02–0.039 as a "prohibited conduct" removal but not a full MIS-reportable violation)
• § 655.41 — Pre-employment drug testing: required before first performance of safety-sensitive duties; the employer may not allow a covered employee or applicant to perform safety-sensitive functions until a verified negative pre-employment drug test result is received from the MRO; no employer may use a test result that is more than 30 days old as the basis for allowing a covered employee to perform safety-sensitive functions for the first time at a new employer

FTA's random drug testing minimum annual rate is 50% of covered employees (same as FMCSA); the random alcohol testing rate is 10% of covered employees. The rates are set based on industry-wide positive test rates and can be adjusted by FTA. Unlike the FMCSA CDL Clearinghouse, there is no FTA equivalent database — previous transit employer drug/alcohol history must be obtained from the prior employer directly. Approximately 650,000 transit workers are covered by Part 655 across roughly 4,500 FTA-funded transit agencies. Recent rulemakings: 78 FR 37993 (June 2013) — last major revision to Part 655; updated alcohol cutoff for removal from duty and clarified post-accident testing procedures.

How It Works

DOT testing operates through a chain of specialized, independent roles designed to ensure integrity and protect employees from arbitrary employer action. The employer (or their Third-Party Administrator) maintains a random testing pool; selection is genuinely random using a scientifically valid method and can happen any day of the year — employees cannot be notified in advance. At the collection site, a trained collector follows strict chain-of-custody procedures using the Federal Custody and Control Form (CCF). The specimen goes to an HHS-certified laboratory for immunoassay screening; if initially positive or non-negative, a GC-MS or LC-MS/MS confirmation test definitively identifies the substance. The laboratory reports all non-negative results to the Medical Review Officer (MRO), not directly to the employer. The MRO then contacts the employee to determine whether a legitimate medical explanation exists (valid prescription, documented medical condition affecting metabolism) before verifying the result. Only after MRO verification does the result reach the employer's Designated Employer Representative (DER). For alcohol, a Breath Alcohol Technician (BAT) administers an initial screening test; any result at or above 0.02% triggers a confirmation test on an evidential breath testing (EBT) device within 15–30 minutes, and the confirmation is the result of record.

Consequences of a verified positive or refusal to test are immediate and mandatory: the employer must remove the employee from safety-sensitive functions before their next shift — there is no discretion, progressive discipline, or waiting period at the removal stage. The employee cannot return to safety-sensitive duties until completing a Substance Abuse Professional (SAP) evaluation, any required treatment or education, a negative return-to-duty drug test, and an ongoing follow-up testing plan (minimum 6 unannounced tests in the first 12 months back). A refusal to test — including adulterating or substituting a specimen, or leaving the collection site without completing the process — is treated the same as a verified positive.

How It Affects You

If you hold a CDL, fly commercially, operate transit vehicles, work on railroads, or work in pipeline operations: You are subject to DOT drug and alcohol testing for the duration of your safety-sensitive employment. Random selection can happen on any workday. A positive result — even for marijuana that is legal in your state — results in immediate removal. Federal DOT testing supersedes state marijuana laws — if you test positive for THC metabolites, the result is verified positive regardless of whether marijuana is legal where you live or work. You have the right to request a split specimen analysis within 72 hours of an MRO-verified positive. If you change DOT-regulated employers, your new employer must check your drug/alcohol testing history for the past two years before you begin safety-sensitive duties.

If you are an employer of CDL drivers, airline employees, or other DOT-regulated workers: You must maintain a written drug and alcohol testing policy, enroll all safety-sensitive employees in a random testing pool, arrange pre-employment testing, conduct post-accident testing following qualifying accidents, and report annual MIS data to your modal agency. You may contract with a TPA to manage the program, but you remain legally responsible for all compliance failures. Before any employee performs their first safety-sensitive duty, you must verify they passed a pre-employment drug test. If you hire from another DOT-regulated employer, you must request and review their prior drug/alcohol testing records.

If you are a supervisor in a DOT-regulated workplace: You must be trained (minimum 60 minutes on drug use signs, 60 minutes on alcohol misuse signs) to make reasonable suspicion determinations. If you observe specific, articulable symptoms of drug or alcohol use during a safety-sensitive duty period, you must document those observations and send the employee for testing. The consequences of not acting — or acting without sufficient basis — are both legal and safety-related.

Recent Rulemakings

• Oral Fluid Testing (May 2023): DOT issued a final rule adding oral fluid (saliva) as an authorized specimen type alongside urine. Oral fluid testing reduces the potential for specimen adulteration and allows observed collection without the privacy concerns of direct observation urine collection. Employers may begin oral fluid testing when SAMHSA certifies oral fluid testing laboratories — laboratory certification was pending as of early 2026.

Recent Developments

• Oral fluid testing awaiting laboratory certification (2026): DOT authorized oral fluid (saliva) testing as a specimen alternative in May 2023, but actual employer use requires SAMHSA-certified laboratories to process oral fluid specimens. As of early 2026, SAMHSA had not yet certified any oral fluid testing laboratories, meaning employers cannot operationally implement oral fluid collection even though the legal authority exists. The delay reflects the complexity of laboratory certification standards for a new specimen type.

• Cannabis and DOT testing tension: With 24+ states having legalized recreational cannabis and federal cannabis reform proposals active in Congress, DOT-regulated employers face a persistent conflict: DOT's testing program remains federal-law-based and marijuana is still a federal Schedule I substance, so safety-sensitive employees who test positive for THC metabolites face consequences regardless of state law. DOT issued guidance reaffirming this position in 2023. Some safety advocates argue the current urine-based THC detection methodology detects past use rather than current impairment, creating compliance burdens unrelated to actual safety risk.

• Expanded DOT workforce categories: The opioid crisis prompted additional regulatory attention on DOT-regulated industries. DOT has issued guidance clarifying that prescription opioids used by safety-sensitive employees are subject to the Medical Review Officer (MRO) review process — employees must proactively disclose prescription medications that could affect performance, and MROs verify legitimate medical use before reporting positive results.

• Return-to-duty SAP program compliance: The Substance Abuse Professional (SAP) evaluation requirement for employees who violate drug/alcohol rules is enforced inconsistently across small employers. DOT has emphasized enforcement of the return-to-duty process, particularly in the trucking and general aviation sectors where small operators have sometimes allowed employees to return without completing the required SAP evaluation and follow-up testing protocol.

• Alcohol testing technology update: Breath alcohol testing devices (EBTs) must be on DOT's Conforming Products List. DOT periodically updates the CPL as new devices are approved and older models are removed. Digital EBT devices with Bluetooth connectivity and cloud-based result transmission are available, but their use in DOT testing requires CPL listing and compliance with record-keeping and tamper-resistance requirements.

• Random Rate Adjustments: DOT modal agencies periodically adjust random testing minimum annual rates based on industry positive test rates. When positive rates fall below 1%, rates can be reduced; when rates rise above program thresholds, rates increase. The FAA's aviation random drug testing rate has been held at 25% of safety-sensitive employees and the random alcohol testing rate at 10% in recent years, including for 2026.